The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa

Ann Hematol. 2014 Oct;93(10):1785-6. doi: 10.1007/s00277-014-2039-7. Epub 2014 Mar 2.

Authors

K T Htun¹, J McFadyen, H A Tran

Affiliation

¹ Department of Haematology, Alfred Health, 55 Commercial Road, Melbourne, Victoria, 3004, Australia, K.Htun@alfred.org.au.

PMID: 24584995
DOI: 10.1007/s00277-014-2039-7

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Benzimidazoles / adverse effects*
Benzimidazoles / therapeutic use
Combined Modality Therapy
Dabigatran
Drainage
Factor VIIa / therapeutic use*
Head Injuries, Closed / complications
Hematoma, Subdural / chemically induced
Hematoma, Subdural / diagnostic imaging
Hematoma, Subdural / drug therapy*
Hematoma, Subdural / etiology
Hematoma, Subdural / surgery
Humans
Hydrocephalus / etiology
Hydrocephalus / surgery
Male
Partial Thromboplastin Time
Recombinant Proteins / therapeutic use
Thrombin Time
Tomography, X-Ray Computed
beta-Alanine / adverse effects
beta-Alanine / analogs & derivatives*
beta-Alanine / therapeutic use

Substances

Benzimidazoles
Recombinant Proteins
beta-Alanine
recombinant FVIIa
Factor VIIa
Dabigatran